MusclePharm to Explore Sale of Its BioZone Laboratories Nevada Subsidiary’s Business

Company Remains Committed to Maximizing Shareholder Value

DENVER–(BUSINESS WIRE)–MusclePharm Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”),
a scientifically driven, performance-lifestyle sports nutrition company,
today announced that it has previously retained an investment banker to
explore the sale of all or substantially all of the assets of its
BioZone Laboratories Inc. subsidiary.

BioZone is a developer, manufacturer, and marketer of over-the-counter
drugs and preparations, cosmetics, and nutritional supplements. BioZone
also develops novel drug delivery platforms, including its QuSome®

“We remain committed to acting in the best interests of our shareholders
and further maximizing shareholder value,” said Ryan Drexler, Executive
Chairman of the Board. “At the end of the day, we are a sales and
marketing company, and that is where we want to focus. As a result, we
are going to concentrate on our core competencies while leaving other
aspects of the business to strategic partners or outside parties who can
bring more expertise to those areas than us.”

As part of this process, MusclePharm has retained investment bank
Canaccord Genuity Inc. to advise the Board of Directors and management
with respect to a sale. The Company said there can be no assurance that
its evaluation process will result in any transaction or that any
transaction, if pursued, will be consummated.

MusclePharm, through a Nevada subsidiary, BioZone Laboratories, acquired
substantially all of the assets of BioZone Pharmaceuticals Inc., a
California company, and its subsidiaries, in January 2014. The
transaction included all assets associated with BioZone’s QuSomes®,
HyperSorb™ and EquaSome™ technologies; BioZone’s Baker-Cummins line of
products; and, the name “BioZone”. BioZone’s patented QuSomes®
technology enhances the absorption of topical and other drugs.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities and Exchange Act of 1934, as amended. Statements that
are not a description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use of
such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”,
“potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”,
“should”, “could” or the negative of such terms or other similar
expressions. Actual results may differ materially from those set forth
in this release due to the risks and uncertainties inherent in the
Company’s business. More detailed information about the Company and the
risk factors that may affect the realization of forward-looking
statements is set forth in the Company’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2014, the Company’s Quarter Reports
on Form 10-Q and other filings submitted by the Company to the SEC,
copies of which may be obtained from the SEC’s website at
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to revise
or update this release to reflect events or circumstances after the date


Sitrick and Company
Seth Lubove, 310-788-2850